Related Experiment Video

Updated: Aug 18, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Positive response of a recurrent clear cell sarcoma to anlotinib combined with chemotherapy: A case report

Junyue Tao1, Hao Yang1, Zongyao Hao1

  • 1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

Medicine
|December 9, 2022
PubMed
Abstract

Insights

This case study shows anlotinib combined with chemotherapy may effectively treat recurrent clear cell sarcoma (CCSK) after initial chemotherapy failure. The patient experienced significant tumor reduction and remained recurrence-free for 8 months post-surgery.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Renal clear cell sarcoma (CCSK) is a rare, aggressive kidney cancer with high recurrence rates.
  • Recurrent CCSK has limited treatment options and poor response to conventional chemotherapy.

Observation:

  • An 18-year-old patient presented with recurrent clear cell sarcoma after radical nephrectomy.
  • Initial chemotherapy proved ineffective for the recurrent tumor.

Findings:

  • The patient received six cycles of anlotinib plus chemotherapy, leading to significant tumor shrinkage.
  • Surgical resection of the residual tumor and affected liver portion was performed.

Implications:

  • This is the first report of anlotinib use in recurrent CCSK.
  • Anlotinib combined with chemotherapy presents a potential novel treatment strategy for recurrent CCSK.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K